TY  - JOUR 
AU  - Gutiérrez Pelaz, Sara
AU  - Flores Hernández, Raquel
AU  - Vujic, Tatjana
AU  - Schvartz, Domitille
AU  - Álvarez Vázquez, Andrea
AU  - Ding, Yuxin
AU  - García Vicente, Laura
AU  - Belloso, Aitana
AU  - Talaverón Aguilocho, Rocío
AU  - Sánchez, Jean Charles
AU  - Tabernero Urbieta, María Aránzazu
PY  - 2024
SN  - 1931-5244
UR  - http://hdl.handle.net/10366/167639
AB  - [EN] Glioblastoma (GBM) is the most frequent and aggressive primary brain cancer. The Src inhibitor, TAT-Cx43266-283, exerts antitumor effects in in vitro and in vivo models of GBM. Because addressing the mechanism of action is essential to translate...
LA  - eng
PB  - Elsevier
KW  - Brain tumors
KW  - Cell-penetrating peptides
KW  - Connexin
KW  - Glioblastoma
KW  - Proteomics
KW  - Src
TI  - A proteomic approach supports the clinical relevance of TAT-Cx43266-283 in glioblastoma
DO  - 10.1016/j.trsl.2024.06.001
T2  - Translational Research
VL  - 272
M2  - 95
ER  -